The groups spend big on Terns and Arcellx.
ApexOnco Front Page
Recent articles
J&J’s Tecvayli/Darzalex nod was the second under a new priority voucher scheme.
The recently unveiled conjugate DS3610a is to start phase 1.
The company is to start a pivotal Chinese trial of its PD-1 x TGF-β-targeting fusion protein.
After menin, the company tries again with farnesyl transferase.
The Rainfol-03 trial, in second-line endometrial cancer, builds on recent early data.
The companies clash over survival curve similarities – and differences.
Petosemtamab's phase 2 data in this setting should come by the year end.
